Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.

Abstract: This invention discloses a DNA fragment encoding a protein comprising the amino acid sequence depicted in FIG. 4 (SEQ ID NO:5), or a protein substantially homologous therewith and involved in fatty aldehyde decarbonylase activity. Said DNA fragment may have the nucleotide sequence depicted in FIG. 2 (SEQ ID NO:2) or a homologous nucleotide sequence. Further this invention discloses a promoter of said DNA fragment having the nucleotide sequence depicted in FIG. 3 (SEQ ID NO:4). Using said fragments transformed organisms can be produced showing an altered epicuticular wax composition.

Abstract: This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

Abstract: The present invention relates to a novel hyaluronan receptor protein involved in cell locomotion or motility and in cell proliferation and transformation and to DNA sequences encoding this protein. The protein is designated Receptor for Hyaluronic Acid Mediated Motility or RHAMM.

Abstract: Urotensin-II Receptor (UTB-R) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Urotensin-II Receptor (UTB-R) polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: Growth differentiation factor Lefty-1 polypeptide and polynucleotides are provided herein. Also disclosed are diagnostic and therapeutic methods of using the Lefty-1 polypeptide and polynucleotide sequences.

Abstract: The effects of endogenous insulin-like growth factor can be appreciated by administering compounds capable of increasing free IGF in living bodies. Compounds are described which can elevate the concentration of unbound IGF by converting endogenous IGF (insulin-like growth factor) into free, biologically active IGF or elevating the concentration of the complex of IGF and IGFBP (insulin-like growth factor binding protein) in living bodies. Medicaments can be prepared containing these compounds or these compounds may be used in methods for the prevention and or treatment of IGF-responsive diseases such as diabetes, amyotrophic lateral sclerosis, or osteoporosis.

Abstract: A human chemotactic polypeptide, DNA (RNA) encoding it, and a procedure for producing such a polypeptide by recombinant techniques are disclosed. Also disclosed are methods of using the polypeptide for a number of purposes, including: stem cell mobilization, myeloprotection, neuronal protection, treating tumors, wound healing, treating parasitic infection, and regulating hematopoiesis. Also disclosed are polypeptide antagonists and diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.

Abstract: Growth differentiation factor-15 (GDF-15) polynucleotide sequence and amino acid sequence are provided herein. Also described are diagnostic and therapeutic methods of using GDF-15 polypeptide and polynucleotide sequences.

Abstract: Highly purified Pluripotent hematopoietic colon-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparent homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM) early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5×108 U/mg protein.

Abstract: The present invention provides a human growth factor receptor binding protein (GRBP) and polynucleotides which encode GRBP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for producing GRBP and for treating disorders associated with expression of GRBP.

Abstract: The invention relates to Cytostatin III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

Abstract: The present invention provides an isolated polypeptide, designated Beta R1, whose production is selectively induced by IFN-&bgr; as compared to IFN-&agr;. The Beta R1 polypeptide is a chemokine whose expression is stimulated in T cells, astrocytes, and fibroblasts that have been—exposed to IFN-&bgr;. The present invention also provides an isolated polynucleotide that encodes the Beta R1 polypeptide and an isolated polynucleotide that encodes the Beta R1 promoter. The present invention also provides a method of identifying putative IFN-&bgr; mimics. In one embodiment, the method comprises the steps of providing cultured cells transfected with a polynucleotide construct that comprises a DNA sequence that encodes the Beta R1 promoter operatively linked to a reporter gene that encodes an assayable product; treating the transfected cells with the putative IFN-&bgr; mimic; and detecting the assayable product produced by the treated cells.

Abstract: The present invention relates to the field of GABA receptor structure and function. In one aspect, the present invention relates to impairment of the gamma-aminobutyric acid (GABA) receptors in parasitic nematodes, for the purpose of crop protection and/or soil treatment. The invention includes mutated nematode GABA receptor subunits, nematode GABA neuromuscular junction receptor complexes, nucleic acids which encode the mutated and functional receptor complexes, antibodies which selectively bind the GABA receptor complexes and/or subunits, and assays for compounds which adversely affect nematode GABA neuromuscular junction receptor function. The present invention therefore relates broadly to recombinant DNA technology, molecular biology tools, and crop protection and/or soil treatment.

Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16,25,49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.

Abstract: This invention discloses a PACAP receptor protein or a salt thereof, a DNA comprising a DNA fragment coding for the protein, a method for preparing the protein, antibody against the protein, and use of the protein, DNA, and antibodies. A PACAP receptor protein was purified from the bovine cerebrum. DNAs coding for PACAP receptor proteins were isolated from bovine, rat and human cDNA libraries, and their nucleotide sequences were determined. Further, amino acid sequences deduced from the nucleotide sequences were determined.

Abstract: This invention relates to the use of lymphotactin or lymphotactin antagonists for administration to an animal. The administration of these therapeutic entities will attract certain cell types, or can be blocked to prevent such attraction. It also provides means to protect stem cells.

Abstract: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.

Abstract: The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. In particular, the polypeptides of the invention comprise amino acid sequences with similarity to EGF-repeat domains.

Abstract: Growth differentiation factor-3 (GDF-3) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-3 polypeptide and polynucleotide sequences.